<div class="row large-10 columns t10">

<ul>

<li><p>
Mitj&agrave;, O., C.&nbsp;Godornes, W.&nbsp;Houinei, A.&nbsp;Kapa, R.&nbsp;Paru, H.&nbsp;Abel,
  C.&nbsp;Gonz&aacute;lez-Beiras, S.&nbsp;V. Bieb, J.&nbsp;Wangi, A.&nbsp;E. Barry, S.&nbsp;Sanz,
  Q.&nbsp;Bassat, and S.&nbsp;A. Lukehart (2018).
 <b>Re-emergence of yaws after single mass azithromycin treatment
  followed by targeted treatment: a longitudinal study</b>.
 <em>The Lancet</em>&nbsp;<em>391</em>(10130), 1599--1607.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S0140-6736(18)30204-6">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920722/pdf/nihms942894.pdf">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Yaws is a substantial cause of chronic disfiguring ulcers in children in at least 14 countries in the tropics. WHO's newly adopted strategy for yaws eradication uses a single round of mass azithromycin treatment followed by targeted treatment programmes, and data from pilot studies have shown a short-term significant reduction of yaws. We assessed the long-term efficacy of the WHO strategy for yaws eradication.
</p></font></blockquote>

</p></li>


<li><p>
Marks, M., O.&nbsp;Mitj&agrave;, C.&nbsp;Bottomley, C.&nbsp;Kwakye, W.&nbsp;Houinei, M.&nbsp;Bauri,
  P.&nbsp;Adwere, A.&nbsp;A. Abdulai, F.&nbsp;Dua, L.&nbsp;Boateng, J.&nbsp;Wangi, S.-A. Ohene,
  R.&nbsp;Wangnapi, S.&nbsp;V. Simpson, H.&nbsp;Miag, K.&nbsp;K. Addo, L.&nbsp;A. Basing, D.&nbsp;Danavall,
  K.&nbsp;H. Chi, A.&nbsp;Pillay, R.&nbsp;Ballard, A.&nbsp;W. Solomon, C.&nbsp;Y. Chen, S.&nbsp;V. Bieb,
  Y.&nbsp;Adu-Sarkodie, D.&nbsp;C.&nbsp;W. Mabey, K.&nbsp;Asiedu, W.&nbsp;Hounei, S.-A. Ohene, S.&nbsp;V.
  Bieb, D.&nbsp;C. Mabey, N.&nbsp;Agana, E.&nbsp;Ampadu, K.&nbsp;Amponsah-Achiano, A.&nbsp;Bediako,
  M.&nbsp;Biredu, K.&nbsp;Faried, A.&nbsp;Iddrisu, N.&nbsp;K. Kotey, G.&nbsp;N. Yeboah, P.&nbsp;El-Duah,
  R.&nbsp;Phillips, F.&nbsp;Binka, F.&nbsp;Nyonator, A.&nbsp;Zunuo, M.&nbsp;A. Ackumey, I.&nbsp;Amanor,
  C.&nbsp;Bnosu, S.&nbsp;Frischmann, P.&nbsp;Lammie, D.&nbsp;Martin, T.&nbsp;Ye, E.&nbsp;Christophel,
  A.&nbsp;Tiendrebeogo, L.&nbsp;Vestergard, Q.&nbsp;Bassat, Y.&nbsp;Abdad, H.&nbsp;Dima, B.&nbsp;Kotty,
  K.&nbsp;Mamore, W.&nbsp;Manup, B.&nbsp;Olowau, E.&nbsp;O. Agyei, D.&nbsp;Agyemang, E.&nbsp;P. Ako,
  P.&nbsp;Antwi, J.&nbsp;Darko, O.&nbsp;O. Darko, P.&nbsp;Darko, B.&nbsp;Duodu, D.&nbsp;Jabasi, F.&nbsp;L. Karim,
  O.&nbsp;K. Koomson, B.&nbsp;A. Labri, J.&nbsp;Nartey, R.&nbsp;Tamatey, B.&nbsp;Yirenkyi, M.&nbsp;Arhin,
  F.&nbsp;Biney, J.&nbsp;O. Danso, M.&nbsp;A. Dei, M.&nbsp;Djan, S.&nbsp;Sasu, B.&nbsp;A. Solomon,
  V.&nbsp;Torvinya, H.&nbsp;Amankwaah, J.&nbsp;Baffoe, L.&nbsp;Keteku, K.&nbsp;Kondobala, R.&nbsp;D. Lomotey,
  A.&nbsp;A. Nartey, P.&nbsp;Oppong, M.&nbsp;A. Quainoo, T.&nbsp;Abotsi, D.&nbsp;Agebshie, A.&nbsp;Ameamu,
  P.&nbsp;Angwaawie, R.&nbsp;Ayibor, M.&nbsp;Mwingmendeli, J.&nbsp;Nakodia, A.&nbsp;Nambagyira,
  D.&nbsp;Nanga, N.&nbsp;Tetteh, and A.&nbsp;Wanaom (2018).
 <b>Comparative efficacy of low-dose versus standard-dose
  azithromycin for patients with yaws: a randomised non-inferiority trial in
  Ghana and Papua New Guinea</b>.
 <em>The Lancet Global Health</em>&nbsp;<em>6</em>(4), e401--e410.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S2214-109X(18)30023-8">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/action/showPdf?pii=S2214-109X%2818%2930023-8">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
A dose of 30 mg/kg of azithromycin is recommended for treatment of yaws, a disease targeted for global eradication. Treatment with 20 mg/kg of azithromycin is recommended for the elimination of trachoma as a public health problem. In some settings, these diseases are co-endemic. We aimed to determine the efficacy of 20 mg/kg of azithromycin compared with 30 mg/kg azithromycin for the treatment of active and latent yaws.
</p></font></blockquote>

</p></li>


<li><p>
Mitj&agrave;, O., C.&nbsp;Gonz&aacute;lez-Beiras, C.&nbsp;Godornes, R.&nbsp;Kolmau, W.&nbsp;Houinei,
  H.&nbsp;Abel, A.&nbsp;Kapa, R.&nbsp;Paru, S.&nbsp;V. Bieb, J.&nbsp;Wangi, S.&nbsp;Sanz, K.&nbsp;Asiedu, S.&nbsp;A.
  Lukehart, and Q.&nbsp;Bassat (2017).
 <b>Effectiveness of single-dose azithromycin to treat latent
  yaws: a longitudinal comparative cohort study</b>.
 <em>The Lancet Global Health</em>&nbsp;<em>5</em>(12), e1268--e1274.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S2214-109X(17)30388-1">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/action/showPdf?pii=S2214-109X%2817%2930388-1">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Treatment of latent yaws is a crucial component of the WHO yaws eradication strategy to prevent relapse and the resulting transmission to uninfected children. We assessed the effectiveness of single-dose azithromycin to treat patients with latent yaws.
</p></font></blockquote>

</p></li>


<li><p>
Mitj√†, O., W.&nbsp;Houinei, P.&nbsp;Moses, A.&nbsp;Kapa, R.&nbsp;Paru, R.&nbsp;Hays, S.&nbsp;Lukehart,
  C.&nbsp;Godornes, S.&nbsp;V. Bieb, T.&nbsp;Grice, P.&nbsp;Siba, D.&nbsp;Mabey, S.&nbsp;Sanz, P.&nbsp;L. Alonso,
  K.&nbsp;Asiedu, and Q.&nbsp;Bassat (2015).
 <b>Mass Treatment with Single-Dose Azithromycin for Yaws</b>.
 <em>New England Journal of Medicine</em>&nbsp;<em>372</em>(8), 703--710.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1056/NEJMoa1408586">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1408586?articleTools=true">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Mass treatment with azithromycin is a central component of the new World Health Organization (WHO) strategy to eradicate yaws. Empirical data on the effectiveness of the strategy are required as a prerequisite for worldwide implementation of the plan.
</p></font></blockquote>

</p></li>


<li><p>
Marks, M., O.&nbsp;Mitj&agrave;, L.&nbsp;S. Vestergaard, A.&nbsp;Pillay, S.&nbsp;Knauf, C.-Y. Chen,
  Q.&nbsp;Bassat, D.&nbsp;L. Martin, D.&nbsp;Fegan, F.&nbsp;Taleo, J.&nbsp;Kool, S.&nbsp;Lukehart, P.&nbsp;M.
  Emerson, A.&nbsp;W. Solomon, T.&nbsp;Ye, R.&nbsp;C. Ballard, D.&nbsp;C.&nbsp;W. Mabey, and K.&nbsp;B.
  Asiedu (2015).
 <b>Challenges and key research questions for yaws eradication</b>.
 <em>The Lancet Infectious Diseases</em>&nbsp;<em>15</em>(10), 1220--1225.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S1473-3099(15)00136-X">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/action/showPdf?pii=S2214-109X%2818%2930023-8">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Yaws is endemic in west Africa, southeast Asia, and the Pacific region. To eradicate yaws by 2020, WHO has launched a campaign of mass treatment with azithromycin. Progress has been made towards achievement of this ambitious goal, including the validation of point-of-care and molecular diagnostic tests and piloting of the strategy in several countries, including Ghana, Vanuatu, and Papua New Guinea. Gaps in knowledge need to be addressed to allow refinement of the eradication strategy. Studies exploring determinants of the spatial distribution of yaws are needed to help with the completion of baseline mapping. The finding that Haemophilus ducreyi causes lesions similar to yaws is particularly important and further work is needed to assess the effect of azithromycin on these lesions. The integration of diagnostic tests into different stages of the eradication campaign needs investigation. Finally, studies must be done to inform the optimum mass-treatment strategy for sustainable interruption of transmission.
</p></font></blockquote>

</p></li>


<li><p>
Mitj&agrave;, O., M.&nbsp;Marks, D.&nbsp;J.&nbsp;P. Konan, G.&nbsp;Ayelo, C.&nbsp;Gonzalez-Beiras, B.&nbsp;Boua,
  W.&nbsp;Houinei, Y.&nbsp;Kobara, E.&nbsp;N. Tabah, A.&nbsp;Nsiire, D.&nbsp;Obvala, F.&nbsp;Taleo,
  R.&nbsp;Djupuri, Z.&nbsp;Zaixing, J.&nbsp;Utzinger, L.&nbsp;S. Vestergaard, Q.&nbsp;Bassat, and
  K.&nbsp;Asiedu (2015).
 <b>Global epidemiology of yaws: a systematic review</b>.
 <em>The Lancet Global Health</em>&nbsp;<em>3</em>(6), e324--e331.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S2214-109X(15)00011-X">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/action/showPdf?pii=S2214-109X%2815%2900011-X">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
To achieve yaws eradication, the use of the new WHO strategy of initial mass treatment with azithromycin and surveillance twice a year needs to be extended everywhere the disease occurs. However, the geographic scope of the disease is unknown. We aimed to synthesise published and unpublished work to update the reported number of people with yaws at national and subnational levels and to estimate at-risk populations.
</p></font></blockquote>

</p></li>


<li><p>
Mitj&agrave;, O., S.&nbsp;A. Lukehart, G.&nbsp;Pokowas, P.&nbsp;Moses, A.&nbsp;Kapa, C.&nbsp;Godornes,
  J.&nbsp;Robson, S.&nbsp;Cherian, W.&nbsp;Houinei, W.&nbsp;Kazadi, P.&nbsp;Siba, E.&nbsp;de&nbsp;Lazzari, and
  Q.&nbsp;Bassat (2014).
 <b><em>haemophilus ducreyi</em> as a cause of skin ulcers in
  children from a yaws-endemic area of papua new guinea: a prospective cohort
  study</b>.
 <em>The Lancet Global Health</em>&nbsp;<em>2</em>(4), e235--e241.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S2214-109X(14)70019-1">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/action/showPdf?pii=S2214-109X%2814%2970019-1">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Skin infections with ulceration are a major health problem in countries of the south Pacific region. Yaws, caused by Treponema pallidum subspecies pertenue and diagnosed by the presence of skin ulcers and a reactive syphilis serology, is one major cause, but this infection can be confused clinically with ulcers due to other causative agents. We investigated T pallidum pertenue and another bacterium known to cause skin infections in the Pacific islands?Haemophilus ducreyi?as causes of skin ulceration in a yaws-endemic region. Additionally, we identified specific signs and symptoms associated with these causative agents of cutaneous ulcers and compared these findings with laboratory-based diagnoses.
</p></font></blockquote>

</p></li>


<li><p>
Ayove, T., W.&nbsp;Houniei, R.&nbsp;Wangnapi, S.&nbsp;V. Bieb, W.&nbsp;Kazadi, L.-N. Luke,
  C.&nbsp;Manineng, P.&nbsp;Moses, R.&nbsp;Paru, J.&nbsp;Esfandiari, P.&nbsp;L. Alonso, E.&nbsp;de&nbsp;Lazzari,
  Q.&nbsp;Bassat, D.&nbsp;Mabey, and O.&nbsp;Mitj&agrave; (2014).
 <b>Sensitivity and specificity of a rapid point-of-care test for
  active yaws: a comparative study</b>.
 <em>The Lancet Global Health</em>&nbsp;<em>2</em>(7), e415--e421.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S2214-109X(14)70231-1">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/action/showPdf?pii=S2214-109X%2814%2970231-1">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
To eradicate yaws, national control programmes use the Morges strategy (initial mass treatment and biannual resurveys). The resurvey component is designed to actively detect and treat remaining yaws cases and is initiated on the basis of laboratory-supported reactive non-treponemal serology (using the rapid plasma reagin [RPR] test). Unfortunately, the RPR test is available rarely in yaws-endemic areas. We sought to assess a new point-of-care assay?the Dual Path Platform (DPP) syphilis assay, which is based on simultaneous detection of antibodies to treponemal and non-treponemal antigens?for guiding use of antibiotics for yaws eradication. A secondary goal was to ascertain at what timepoint the DPP assay line reverted to negative after treatment.
</p></font></blockquote>

</p></li>


<li><p>
Mitj&agrave;, O., K.&nbsp;Asiedu, and D.&nbsp;Mabey (2013).
 <b>Yaws</b>.
 <em>The Lancet</em>&nbsp;<em>381</em>(9868), 763--773.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S0140-6736(12)62130-8">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/journals/lancet/subscribe?backUri=%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736%2812%2962130-8%2Ffulltext%3Ffromsource%3Dnelm&amp;offerId=13%2C10.1016%2FS0140-6736%2812%2962130-8&amp;addToCart=true">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Yaws is an infectious disease caused by Treponema pallidum pertenue?a bacterium that closely resembles the causative agent of syphilis?and is spread by skin-to-skin contact in humid tropical regions. Yaws causes disfiguring, and sometimes painful lesions of the skin and bones. As with syphilis, clinical manifestations can be divided into three stages; however, unlike syphilis, mother-to-child transmission does not occur. A major campaign to eradicate yaws in the 1950s and 1960s, by mass treatment of affected communities with longacting, injectable penicillin, reduced the number of cases by 95% worldwide, but yaws has reappeared in recent years in Africa, Asia, and the western Pacific. In 2012, one oral dose of azithromycin was shown to be as effective as intramuscular penicillin in the treatment of the disease, and WHO launched a new initiative to eradicate yaws by 2020.
</p></font></blockquote>

</p></li>


<li><p>
Mitj&agrave;, O., R.&nbsp;Hays, A.&nbsp;Ipai, M.&nbsp;Penias, R.&nbsp;Paru, D.&nbsp;Fagaho, E.&nbsp;de&nbsp;Lazzari,
  and Q.&nbsp;Bassat (2012).
 <b>Single-dose azithromycin versus benzathine benzylpenicillin
  for treatment of yaws in children in Papua New Guinea: an open-label,
  non-inferiority, randomised trial</b>.
 <em>The Lancet</em>&nbsp;<em>379</em>(9813), 342--347.
[&nbsp;<a target="_blank" href="http://dx.doi.org/10.1016/S0140-6736(11)61624-3">DOI</a>&nbsp;| 
<a target="_blank" href="https://www.thelancet.com/journals/lancet/subscribe">ePrint</a>&nbsp;]
<blockquote><font size="-1"><p>
Yaws is an endemic treponematosis and, as such, a neglected tropical disease?is re-emerging in children in rural, tropical areas. Oral azithromycin is effective for syphilis. We assessed the efficacy of azithromycin compared with intramuscular long-acting penicillin to treat patients with yaws.
</p></font></blockquote>

</p></li>
</ul></div>
